Mechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression

Figure 10  Expression of brain-derived neurotrophic factor and tropomyosin receptor kinase B proteins in the hippocampus. A: Expression of brain-derived neurotrophic factor (BDNF) protein in depression groups; B: Expression of tropomyosin receptor kinase B (TrkB) protein in depression groups; C: Density analysis of BDNF and TrkB protein expressions in depression groups; D: Expression of BDNF protein in chronic restraint stress (CUMS), dextran sodium sulfate (DSS) and compound model groups; E: Expression of TrkB protein in CUMS, DSS and compound model groups; F: Density analysis of BDNF and TrkB protein expressions in CUMS, DSS and compound model groups. ^aP < 0.01 vs control group; ^bP < 0.01 vs chronic restraint stress group; ^cP < 0.01 vs chronic restraint stress + dextran sodium sulfate group; ^gP < 0.05 vs chronic restraint stress group; ^hP < 0.05 vs chronic restraint stress + dextran sodium sulfate group. CUMS: Chronic restraint stress; DSS: Dextran sodium sulfate; LD: Low-dose Wuling powder; MD: Medium-dose Wuling powder; HD: High-dose Wuling powder; FLU: Fluoxetine; MS: Mesalazine; BDNF: Brain-derived neurotrophic factor; TrkB: Tropomyosin receptor kinase B.